Kevin Outterson is a lawyer, a professor of law and the N. Neal Pike Scholar in Health and Disability Law at Boston University (2014–present). He is also the founding executive director and principal investigator of Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership that supports companies developing new antibiotics, diagnostics, vaccines and other products to address drug-resistant bacterial infections. CARB-X is funded by the United States, United Kingdom and German governments, Wellcome and the Bill & Melinda Gates Foundation. In 2022, CARB-X received a new commitment of funding from BARDA and Wellcome of up to $370 million. The G7 Health Ministers have cited CARB-X among the critical initiatives to support as the G7 governmen
Property | Value |
---|---|
dbo:abstract |
|
dbo:almaMater | |
dbo:employer | |
dbo:knownFor | |
dbo:nationality | |
dbo:occupation | |
dbo:wikiPageExternalLink |
|
dbo:wikiPageID |
|
dbo:wikiPageLength |
|
dbo:wikiPageRevisionID |
|
dbo:wikiPageWikiLink |
|
dbp:almaMater | |
dbp:employer | |
dbp:knownFor |
|
dbp:name |
|
dbp:occupation |
|
dbp:wikiPageUsesTemplate | |
dcterms:subject | |
schema:sameAs | |
rdf:type | |
rdfs:comment |
|
rdfs:label |
|
owl:sameAs | |
prov:wasDerivedFrom | |
foaf:isPrimaryTopicOf | |
foaf:name |
|
is dbo:wikiPageRedirects of | |
is dbo:wikiPageWikiLink of | |
is foaf:primaryTopic of |